HPV Vaccination in Populations with High HIV Prevalence

Cervical Cancer Action's new three-page brief provides guidance on use of HPV vaccine in areas where HIV infection is high. Key messages from the paper include:

  • HPV infection doubles the risk of acquiring HIV in women and men. HIV also significantly increases the risk of persistent HPV infections, which can lead to cervical cancer.
  • Studies show that HIV-infected women have the ability to mount the necessary immune response to HPV antigens—that is, they have the biological capacity to benefit from the vaccine.
  • The potential benefit of the vaccine may be great due to this group's increased risk for HPV-related disease.


Currently available in English, CCA is translating the brief into both Spanish and French. Look for updates in a future CCA News Brief.

Three resources from World Health Organization

  • HPV Vaccine Communication: Special considerations for a unique vaccine This World Health Organization (WHO) document (WHO/IVB/13.12) includes assessments of social mobilization and communication of HPV vaccine implementation in Latvia, Malaysia, and Rwanda as well as information from a gathering to review HPV vaccine communication issues. Currently available in English, a French translation is underway.
  • Monitoring national cervical cancer prevention and control programmes A new guide from WHO and the Pan American Health Organization (PAHO) outlines quality control and quality assurance considerations to support introduction or scale-up of visual inspection with acetic acid (VIA) as a screening test for cervical cancer. It is intended primarily for programme managers, supervisors and other stakeholders working in public health programmes for cervical cancer prevention and control.
  • HPV Vaccine Introduction Clearing House The World Health Organization has collected all their materials related to HPV vaccine introduction in one place with the intention of helping guide HPV vaccine policy, program, and communications managers in the development of successful strategies for the introduction and sustained delivery of HPV vaccination at a national level.